CLDX — Celldex Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.27bn
- $1.55bn
- $1.55m
U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen
Celldex climbs after Barclays' double upgrade
Brief: Celldex Therapeutics Offers 10,345,000 Shares Of Common Stock - SEC Filing
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
U.S. STOCKS ON THE MOVE-Globalstar, Wingstop, US energy stocks
Celldex Therapeutics slips on $300 mln share sale
Brief: Celldex Announces Pricing Of $300 Million Public Offering Of Common Stock
Brief: Celldex Announces Proposed Public Offering Of Common Stock
Celldex Therapeutics drops on unveiling stock offering
Brief: Celldex Therapeutics Presents Positive Phase 2 Data For Barzolvolimab In CSU, ColdU, And SD
Celldex Q4 revenue falls
Brief: Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria
Brief: Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism
Clinical-stage biotech Celldex's Q3 net loss widens to $67 mln
U.S. STOCKS ON THE MOVE-Dayforce, gold miners, Regeneron
U.S. STOCKS ON THE MOVE-Snowflake, silver miners, oil firms
Celldex Therapeutics tumbles after halting development of esophagus drug
Celldex Therapeutics falls on stopping development of drug for esophageal condition